EGFR and breast cancer: Taken together, this suggests that ERBB2 requires EGFR or other members of the family possibly to dimerize for activation, such that down‐regulation of EGFR and potentially other members suppress the functionality of ERBB2, as has been previously reported in breast cancer.46